Service d'hépatologie, Hôpital Beaujon, APHP, University Paris-Diderot and INSERM CRB3, 100 Bd du Général Leclerc, 92110 Clichy, France.
Best Pract Res Clin Gastroenterol. 2012 Aug;26(4):455-62. doi: 10.1016/j.bpg.2012.09.003.
Approximately 170 million people are infected with hepatitis C virus (HCV) worldwide. Sustained virological response (SVR) is equivalent to viral eradication and associated with a reduction in the risk of cirrhosis and hepatocellular carcinoma. The treatment for genotype 1 HCV chronic infection is the addition of a protease inhibitor (telaprevir or boceprevir) to the pegylated-interferon (PEG-IFN) plus ribavirin (RBV) regimen. Treatment of genotype 1 naïve chronic hepatitis C with PEG-IFN and ribavirin (RBV) for 48 weeks results in SVR in approximately 40% of patients. Retreatment of previous relapsers to PEG-IFN/RBV therapy with triple therapy, a protease inhibitor (telaprevir or boceprevir), plus PEG-IFN and RBV results in SVR in more than 70% of cases. However, retreatment of previous non-responders to PEG-IFN/RBV therapy with these triple therapies, results in SVR in less than 30% of cases. The aim of this review is to summarize results obtained with Boceprevir or Telaprevir triple therapy for prior HCV experienced patients (non-responders and relapsers).
全球约有 1.7 亿人感染丙型肝炎病毒（HCV）。持续病毒学应答（SVR）相当于病毒清除，并可降低肝硬化和肝细胞癌的风险。治疗 1 型丙型肝炎慢性感染是在聚乙二醇干扰素（PEG-IFN）加利巴韦林（RBV）方案中添加蛋白酶抑制剂（telaprevir 或 boceprevir）。PEG-IFN 和利巴韦林（RBV）治疗 48 周治疗 1 型丙型肝炎慢性感染的患者中，约有 40%的患者达到 SVR。用三药疗法（蛋白酶抑制剂（telaprevir 或 boceprevir）加 PEG-IFN 和 RBV）对以前用 PEG-IFN/RBV 治疗复发的患者进行再治疗，SVR 率超过 70%。然而，用这些三药疗法对以前用 PEG-IFN/RBV 治疗无应答的患者进行再治疗，SVR 率低于 30%。本综述的目的是总结博西普韦或特拉普韦三联疗法治疗既往丙型肝炎感染患者（无应答者和复发者）的结果。
